1
|
Hezinger L, Bauer S, Ellwanger K, Piotrowsky A, Biber F, Venturelli S, Kufer TA. NOD1 cooperates with HAX-1 to promote cell migration in a RIPK2- and NF-ĸB-independent manner. FEBS J 2023; 290:5295-5312. [PMID: 37488967 DOI: 10.1111/febs.16912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 06/13/2023] [Accepted: 07/21/2023] [Indexed: 07/26/2023]
Abstract
The human Nod-like receptor protein NOD1 is a well-described pattern-recognition receptor (PRR) with diverse functions. NOD1 associates with F-actin and its protein levels are upregulated in metastatic cancer cells. A hallmark of cancer cells is their ability to migrate, which involves actin remodelling. Using chemotaxis and wound healing assays, we show that NOD1 expression correlated with the migration rate and chemotactic index in the cervical carcinoma cell line HeLa. The effect of NOD1 in cell migration was independent of the downstream kinase RIPK2 and NF-ĸB activity. Additionally, NOD1 negatively regulated the phosphorylation status of cofilin, which inhibits actin turnover. Co-immunoprecipitation assays identified HCLS1-associated protein X-1 (HAX-1) as a previously unknown interaction partner of NOD1. Silencing of HAX-1 expression reduced the migration behaviour to similar levels as NOD1 knockdown, and simultaneous knockdown of NOD1 and HAX-1 showed no additive effect, suggesting that both proteins act in the same pathway. In conclusion, our data revealed an important role of the PRR NOD1 in regulating cell migration as well as chemotaxis in human cervical cancer cells and identified HAX-1 as a protein that interacts with NOD1 and is involved in this signalling pathway.
Collapse
Affiliation(s)
- Lucy Hezinger
- Department of Immunology, Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany
| | - Sarah Bauer
- Department of Immunology, Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany
| | - Kornelia Ellwanger
- Department of Immunology, Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany
| | - Alban Piotrowsky
- Department of Biochemistry of Nutrition, University of Hohenheim, Stuttgart, Germany
| | - Felix Biber
- Department of Immunology, Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany
| | - Sascha Venturelli
- Department of Biochemistry of Nutrition, University of Hohenheim, Stuttgart, Germany
- Department of Vegetative and Clinical Physiology, Institute of Physiology, University Hospital Tuebingen, Germany
| | - Thomas A Kufer
- Department of Immunology, Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany
| |
Collapse
|
2
|
Trindade BC, Chen GY. NOD1 and NOD2 in inflammatory and infectious diseases. Immunol Rev 2020; 297:139-161. [PMID: 32677123 DOI: 10.1111/imr.12902] [Citation(s) in RCA: 114] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 06/23/2020] [Accepted: 06/24/2020] [Indexed: 12/12/2022]
Abstract
It has been long recognized that NOD1 and NOD2 are critical players in the host immune response, primarily by their sensing bacterial peptidoglycan-conserved motifs. Significant advances have been made from efforts that characterize their upstream activators, assembly of signaling complexes, and activation of downstream signaling pathways. Disruption in NOD1 and NOD2 signaling has also been associated with impaired host defense and resistance to the development of inflammatory diseases. In this review, we will describe how NOD1 and NOD2 sense microbes and cellular stress to regulate host responses that can affect disease pathogenesis and outcomes.
Collapse
Affiliation(s)
- Bruno C Trindade
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Grace Y Chen
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
3
|
Kwon MY, Hwang N, Lee SJ, Chung SW. Nucleotide-binding oligomerization domain protein 2 attenuates ER stress-induced cell death in vascular smooth muscle cells. BMB Rep 2020. [PMID: 31619316 PMCID: PMC6889894 DOI: 10.5483/bmbrep.2019.52.11.176] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Nucleotide-binding oligomerization domain protein 2 (NOD2), an intracellular pattern recognition receptor, plays important roles in inflammation and cell death. Previously, we have shown that NOD2 is expressed in vascular smooth muscle cells (VSMCs) and that NOD2 deficiency promotes VSMC proliferation, migration, and neointimal formation after vascular injury. However, its role in endoplasmic reticulum (ER) stress-induced cell death in VSMCs remains unclear. Thus, the objective of this study was to evaluate ER stress-induced viability of mouse primary VSMCs. NOD2 deficiency increased ER stress-induced cell death and expression levels of apoptosis mediators (cleaved caspase-3, Bax, and Bak) in VSMCs in the presence of tunicamycin (TM), an ER stress inducer. In contrast, ER stress-induced cell death and expression levels of apoptosis mediators (cleaved caspase-3, Bax, and Bak) were decreased in NOD2-overexpressed VSMCs. We found that the IRE-1α-XBP1 pathway, one of unfolded protein response branches, was decreased in NOD2-deficient VSMCs and reversed in NOD2-overexpressed VSMCs in the presence of TM. Furthermore, NOD2 deficiency reduced the expression of XBP1 target genes such as GRP78, PDI-1, and Herpud1, thus improving cell survival. Taken together, these data suggest that the induction of ER stress through NOD2 expression can protect against TM-induced cell death in VSMCs. These results may contribute to a new paradigm in vascular homeostasis. [BMB Reports 2019; 52(11): 665-670].
Collapse
Affiliation(s)
- Min-Young Kwon
- School of Biological Sciences, University of Ulsan, Ulsan 44610, Korea
| | - Narae Hwang
- School of Biological Sciences, University of Ulsan, Ulsan 44610, Korea
| | - Seon-Jin Lee
- Environmental Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea
| | - Su Wol Chung
- School of Biological Sciences, University of Ulsan, Ulsan 44610, Korea
| |
Collapse
|
4
|
Kwon MY, Hwang N, Back SH, Lee SJ, Perrella MA, Chung SW. Nucleotide-binding oligomerization domain protein 2 deficiency enhances CHOP expression and plaque necrosis in advanced atherosclerotic lesions. FEBS J 2020; 287:2055-2069. [PMID: 32167239 PMCID: PMC7318642 DOI: 10.1111/febs.15294] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 02/04/2020] [Accepted: 03/11/2020] [Indexed: 02/05/2023]
Abstract
Endoplasmic reticulum (ER) stress-induced cell death of vascular smooth muscle cells (VSMCs) is extensively involved in atherosclerotic plaque stabilization. We previously reported that nucleotide-binding oligomerization domain protein 2 (NOD2) participated in vascular homeostasis and tissue injury. However, the role and underlying mechanisms of NOD2 remain unknown in ER stress-induced cell death of VSMC during vascular diseases, including advanced atherosclerosis. Here, we report that NOD2 specifically interacted with ER stress sensor activating transcription factor 6 (ATF6) and suppressed the expression of proapoptotic transcription factor CHOP (C/EBP homologous protein) during ER stress. CHOP-positive cells were increased in neointimal lesions after femoral artery injury in NOD2-deficient mice. In particular, a NOD2 ligand, MDP, and overexpression of NOD2 decreased CHOP expression in wild-type VSMCs. NOD2 interacted with an ER stress sensor molecule, ATF6, and acted as a negative regulator for ATF6 activation and its downstream target molecule, CHOP, that regulates ER stress-induced apoptosis. Moreover, NOD2 deficiency promoted disruption of advanced atherosclerotic lesions and CHOP expression in NOD2-/- ApoE-/- mice. Our findings indicate an unsuspected critical role for NOD2 in ER stress-induced cell death.
Collapse
Affiliation(s)
- Min-Young Kwon
- Laboratory of Molecular Immunology, Department of Biological Sciences, University of Ulsan, South Korea.,Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Narae Hwang
- Laboratory of Molecular Immunology, Department of Biological Sciences, University of Ulsan, South Korea
| | - Sung Hoon Back
- Laboratory of Molecular Immunology, Department of Biological Sciences, University of Ulsan, South Korea
| | - Seon-Jin Lee
- Environmental Disease Research Center, KRIBB, Daejeon, Korea
| | - Mark A Perrella
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Su Wol Chung
- Laboratory of Molecular Immunology, Department of Biological Sciences, University of Ulsan, South Korea
| |
Collapse
|
5
|
Baron RM, Kwon MY, Castano AP, Ghanta S, Riascos-Bernal DF, Lopez-Guzman S, Macias AA, Ith B, Schissel SL, Lederer JA, Reeves R, Yet SF, Layne MD, Liu X, Perrella MA. Frontline Science: Targeted expression of a dominant-negative high mobility group A1 transgene improves outcome in sepsis. J Leukoc Biol 2018; 104:677-689. [PMID: 29975792 PMCID: PMC6431081 DOI: 10.1002/jlb.4hi0817-333rr] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 05/30/2018] [Accepted: 05/31/2018] [Indexed: 01/24/2023] Open
Abstract
High mobility group (HMG) proteins are a family of architectural transcription factors, with HMGA1 playing a role in the regulation of genes involved in promoting systemic inflammatory responses. We speculated that blocking HMGA1-mediated pathways might improve outcomes from sepsis. To investigate HMGA1 further, we developed genetically modified mice expressing a dominant negative (dn) form of HMGA1 targeted to the vasculature. In dnHMGA1 transgenic (Tg) mice, endogenous HMGA1 is present, but its function is decreased due to the mutant transgene. These mice allowed us to specifically study the importance of HMGA1 not only during a purely pro-inflammatory insult of endotoxemia, but also during microbial sepsis induced by implantation of a bacterial-laden fibrin clot into the peritoneum. We found that the dnHMGA1 transgene was only present in Tg and not wild-type (WT) littermate mice, and the mutant transgene was able to interact with transcription factors (such as NF-κB), but was not able to bind DNA. Tg mice exhibited a blunted hypotensive response to endotoxemia, and less mortality in microbial sepsis. Moreover, Tg mice had a reduced inflammatory response during sepsis, with decreased macrophage and neutrophil infiltration into tissues, which was associated with reduced expression of monocyte chemotactic protein-1 and macrophage inflammatory protein-2. Collectively, these data suggest that targeted expression of a dnHMGA1 transgene is able to improve outcomes in models of endotoxin exposure and microbial sepsis, in part by modulating the immune response and suggest a novel modifiable pathway to target therapeutics in sepsis.
Collapse
Affiliation(s)
- Rebecca M. Baron
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Min-Young Kwon
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Ana P. Castano
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Sailaja Ghanta
- Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Dario F. Riascos-Bernal
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
- Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine, Bronx NY 10461
| | - Silvia Lopez-Guzman
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Alvaro Andres Macias
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
- Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Bonna Ith
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Scott L. Schissel
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - James A. Lederer
- Department of Surgery, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Raymond Reeves
- Department of Chemistry, School of Molecular Biosciences, and Institute of Biological Chemistry, Washington State University, Pullman, WA 99164
| | - Shaw-Fang Yet
- Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Taiwan
| | - Matthew D. Layne
- Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118
| | - Xiaoli Liu
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
- Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| | - Mark A. Perrella
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
- Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
| |
Collapse
|
6
|
Kwon MY, Hwang N, Park YJ, Perrella MA, Chung SW. NOD2 deficiency exacerbates hypoxia-induced pulmonary hypertension and enhances pulmonary vascular smooth muscle cell proliferation. Oncotarget 2018; 9:12671-12681. [PMID: 29560100 PMCID: PMC5849164 DOI: 10.18632/oncotarget.23912] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Accepted: 11/03/2017] [Indexed: 01/12/2023] Open
Abstract
Expression of nucleotide-binding oligomerization domain protein 2 (NOD2) is upregulated in pulmonary artery smooth muscle cells (PASMCs) during hypoxia. To investigate the involvement of NOD2 in the pulmonary vascular response to hypoxia, we subjected wild-type and NOD2-deficient mice to chronic normobaric hypoxic conditions. Compared to wild-type mice, NOD2-deficient mice developed severe pulmonary hypertension with exaggerated elevation of right ventricular systolic pressure, profound right ventricular hypertrophy and striking vascular remodeling after exposure to hypoxia. Pulmonary vascular remodeling in NOD2-deficient mice was characterized by increased PASMC proliferation. Furthermore, hypoxia-inducible factor-1α expression and Akt phosphorylation were upregulated in PASMCs from NOD2-deficient mice exposed to hypoxia. Our findings revealed that the absence of NOD2 exacerbated hypoxia-induced PASMC proliferation, pulmonary hypertension and vascular remodeling, but had no effect on PASMC migration or contractility.
Collapse
Affiliation(s)
- Min-Young Kwon
- School of Biological Sciences, College of Natural Sciences, University of Ulsan, Ulsan, South Korea
| | - Narae Hwang
- School of Biological Sciences, College of Natural Sciences, University of Ulsan, Ulsan, South Korea
| | - Young-Jun Park
- Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, Yuseong-gu, Daejeon, South Korea
| | - Mark A Perrella
- Division of Pulmonary and Critical Care, Department of Medicine, and Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Su Wol Chung
- School of Biological Sciences, College of Natural Sciences, University of Ulsan, Ulsan, South Korea
| |
Collapse
|
7
|
Bomfim GF, Rodrigues FL, Carneiro FS. Are the innate and adaptive immune systems setting hypertension on fire? Pharmacol Res 2017; 117:377-393. [PMID: 28093357 DOI: 10.1016/j.phrs.2017.01.010] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Revised: 12/06/2016] [Accepted: 01/09/2017] [Indexed: 02/08/2023]
Abstract
Hypertension is the most common chronic cardiovascular disease and is associated with several pathological states, being an important cause of morbidity and mortality around the world. Low-grade inflammation plays a key role in hypertension and the innate and adaptive immune systems seem to contribute to hypertension development and maintenance. Hypertension is associated with vascular inflammation, increased vascular cytokines levels and infiltration of immune cells in the vasculature, kidneys and heart. However, the mechanisms that trigger inflammation and immune system activation in hypertension are completely unknown. Cells from the innate immune system express pattern recognition receptors (PRR), which detect conserved pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) that induce innate effector mechanisms to produce endogenous signals, such as inflammatory cytokines and chemokines, to alert the host about danger. Additionally, antigen-presenting cells (APC) act as sentinels that are activated by PAMPs and DAMPs to sense the presence of the antigen/neoantigen, which ensues the adaptive immune system activation. In this context, different lymphocyte types are activated and contribute to inflammation and end-organ damage in hypertension. This review will focus on experimental and clinical evidence demonstrating the contribution of the innate and adaptive immune systems to the development of hypertension.
Collapse
Affiliation(s)
- Gisele F Bomfim
- Institute of Health Sciences, Federal University of Mato Grosso, Sinop, MT, Brazil
| | - Fernanda Luciano Rodrigues
- Department of Physiology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil
| | - Fernando S Carneiro
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Av Bandeirantes, 3900, 14049-900 Ribeirao Preto, SP, Brazil.
| |
Collapse
|
8
|
NOD2 contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and inflammation. Life Sci 2016; 149:10-7. [DOI: 10.1016/j.lfs.2016.02.039] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 01/05/2016] [Accepted: 02/09/2016] [Indexed: 01/06/2023]
|
9
|
Abstract
SIGNIFICANCE Pattern-recognition receptors (PRRs) are a family of receptors that are used to detect pathogen-associated molecular patterns or damage-associated molecular patterns, which initiate immune responses to resolve infections and repair damaged tissues. Abnormalities in PRR activation will unavoidably lead to excessive inflammation. RECENT ADVANCES Although multiple pathophysiological processes are involved in cardiovascular disease, recent studies have highlighted the importance of innate PRRs, in particular, Toll-like receptors and nucleotide-binding oligomerization domain-like receptors, in mediating inflammatory responses and cardiovascular function. CRITICAL ISSUES The functional roles and regulatory mechanisms of PRRs in cardiovascular diseases are still largely unknown. In particular, controversies exist on the certainty of these detrimental or beneficial effects of some PRRs in different diseased states or different experimental animal models. FUTURE DIRECTIONS Considering that the molecular mechanisms for individual PRR to regulate cellular function are complex and multiple PRRs are activated simultaneously or synergistically, a better understanding of the function of individual PRRs and the interplay of PRRs will provide unexpected opportunities to develop new therapies for cardiovascular disease by modulation of an innate immune system.
Collapse
Affiliation(s)
- Xiaojie Wang
- Department of Pharmacology, Shandong University School of Medicine , Jinan, China
| | | |
Collapse
|
10
|
Zhang H, Zhu T, Liu W, Qu X, Chen Y, Ren P, Wang Z, Wei X, Zhang Y, Yi F. TIPE2 acts as a negative regulator linking NOD2 and inflammatory responses in myocardial ischemia/reperfusion injury. J Mol Med (Berl) 2015; 93:1033-43. [DOI: 10.1007/s00109-015-1288-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Revised: 03/17/2015] [Accepted: 03/31/2015] [Indexed: 12/14/2022]
|
11
|
Tsoyi K, Geldart AM, Christou H, Liu X, Chung SW, Perrella MA. Elk-3 is a KLF4-regulated gene that modulates the phagocytosis of bacteria by macrophages. J Leukoc Biol 2014; 97:171-80. [PMID: 25351511 DOI: 10.1189/jlb.4a0214-087r] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
ETS family proteins play a role in immune responses. A unique member of this family, Elk-3, is a transcriptional repressor that regulates the expression of HO-1. Elk-3 is very sensitive to the effects of inflammatory mediators and is down-regulated by bacterial endotoxin (LPS). In the present study, exposure of mouse macrophages to Escherichia coli LPS resulted in decreased, full-length, and splice-variant isoforms of Elk-3. We isolated the Elk-3 promoter and demonstrated that LPS also decreased promoter activity. The Elk-3 promoter contains GC-rich regions that are putative binding sites for zinc-finger transcription factors, such as Sp1 and KLFs. Mutation of the GC-rich region from bp -613 to -603 blunted LPS-induced down-regulation of the Elk-3 promoter. Similar to the LPS response, coexpression of KLF4 led to repression of Elk-3 promoter activity, whereas coexpression of Sp1 increased activity. ChIP assays revealed that KLF4 binding to the Elk-3 promoter was increased by LPS exposure, and Sp1 binding was decreased. Thus, down-regulation of Elk-3 by bacterial LPS is regulated, in part, by the transcriptional repressor KLF4. Overexpression of Elk-3, in the presence of E. coli bacteria, resulted in decreased macrophage phagocytosis. To determine whether limited expression of HO-1 may contribute to this response, we exposed HO-1-deficient bone marrow-derived macrophages to E. coli and found a comparable reduction in bacterial phagocytosis. These data suggest that down-regulation of Elk-3 and the subsequent induction of HO-1 are important for macrophage function during the inflammatory response to infection.
Collapse
Affiliation(s)
- Konstantin Tsoyi
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and
| | - Adriana M Geldart
- Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; Division of Newborn Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA; and
| | - Helen Christou
- Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; Division of Newborn Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA; and
| | - Xiaoli Liu
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Su Wol Chung
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and School of Biological Sciences, University of Ulsan, South Korea
| | - Mark A Perrella
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA;
| |
Collapse
|
12
|
Johansson ME, Zhang XY, Edfeldt K, Lundberg AM, Levin MC, Borén J, Li W, Yuan XM, Folkersen L, Eriksson P, Hedin U, Low H, Sviridov D, Rios FJ, Hansson GK, Yan ZQ. Innate immune receptor NOD2 promotes vascular inflammation and formation of lipid-rich necrotic cores in hypercholesterolemic mice. Eur J Immunol 2014; 44:3081-92. [PMID: 25042478 DOI: 10.1002/eji.201444755] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Revised: 06/16/2014] [Accepted: 07/14/2014] [Indexed: 01/07/2023]
Abstract
Atherosclerosis is an inflammatory disease associated with the activation of innate immune TLRs and nucleotide-binding oligomerization domain-containing protein (NOD)-like receptor pathways. However, the function of most innate immune receptors in atherosclerosis remains unclear. Here, we show that NOD2 is a crucial innate immune receptor influencing vascular inflammation and atherosclerosis severity. 10-week stimulation with muramyl dipeptide (MDP), the NOD2 cognate ligand, aggravated atherosclerosis, as indicated by the augmented lesion burden, increased vascular inflammation and enlarged lipid-rich necrotic cores in Ldlr(-/-) mice. Myeloid-specific ablation of NOD2, but not its downstream kinase, receptor-interacting serine/threonine-protein kinase 2, restrained the expansion of the lipid-rich necrotic core in Ldlr(-/-) chimeric mice. In vitro stimulation of macrophages with MDP enhanced the uptake of oxidized low-density lipoprotein and impaired cholesterol efflux in concordance with upregulation of scavenger receptor A1/2 and downregulation of ATP-binding cassette transporter A1. Ex vivo stimulation of human carotid plaques with MDP led to increased activation of inflammatory signaling pathways p38 MAPK and NF-κB-mediated release of proinflammatory cytokines. Altogether, this study suggests that NOD2 contributes to the expansion of the lipid-rich necrotic core and promotes vascular inflammation in atherosclerosis.
Collapse
Affiliation(s)
- Maria E Johansson
- Center for Molecular Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden; Department of Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss. Proc Natl Acad Sci U S A 2013; 110:E5059-68. [PMID: 24324141 DOI: 10.1073/pnas.1320862110] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
The purpose of this study was to elucidate the role of nucleotide binding oligomerization domain-containing protein 2 (NOD2) signaling in atherosclerosis and periodontal bone loss using an Apolipoprotein E(-/-) (ApoE(-/-)) mouse model based on the proposed role of NOD2 in inflammation. NOD2(-/-)ApoE(-/-) and ApoE(-/-) mice fed a standard chow diet were given an oral gavage of Porphyromonas gingivalis for 15 wk. NOD2(-/-)ApoE(-/-) mice exhibited significant increases in inflammatory cytokines, alveolar bone loss, cholesterol, and atherosclerotic lesions in the aorta and the heart compared with ApoE(-/-) mice. In contrast, ApoE(-/-) mice injected i.p. with Muramyl DiPeptide (MDP) to stimulate NOD2 and given an oral gavage of P. gingivalis displayed a reduction of serum inflammatory cytokines, alveolar bone loss, cholesterol, and atherosclerotic lesions in the aorta and aortic sinus compared with ApoE(-/-) mice orally challenged but injected with saline. A reduction in body weight gain was observed in ApoE(-/-) mice fed a high-fat diet (HFD) and injected with MDP compared with ApoE(-/-) mice fed a high-fat diet but injected with saline. MDP treatment of bone marrow-derived macrophages incubated with P. gingivalis increased mRNA expressions of NOD2, Toll-like receptor 2, myeloid differentiation primary response gene 88, and receptor-interacting protein-2 but reduced the expressions of inhibitor of NF-κB kinase-β, NF-κB, c-Jun N-terminal kinase 3, and TNF-α protein levels compared with saline control, highlighting pathways involved in MDP antiinflammatory effects. MDP activation of NOD2 should be considered in the treatment of inflammatory processes affecting atherosclerosis, periodontal bone loss ,and possibly, diet-induced weight gain.
Collapse
|
14
|
Han H, Yi F. New insights into TRP channels: Interaction with pattern recognition receptors. Channels (Austin) 2013; 8:13-9. [PMID: 24299922 DOI: 10.4161/chan.27178] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
An increasing number of studies have implicated that the activation of innate immune system and inflammatory mechanisms are of importance in the pathogenesis of numerous diseases. The innate immune system is present in almost all multicellular organisms in response to pathogens or tissue injury, which is performed via germ-line encoded pattern-recognition receptors (PRRs) to recognize pathogen-associated molecular patterns (PAMPs) or dangers-associated molecular patterns (DAMPs). Intracellular pathways linking immune and inflammatory response to ion channel expression and function have been recently identified. Among ion channels, transient receptor potential (TRP) channels are a major family of non-selective cation-permeable channels that function as polymodal cellular sensors involved in many physiological and pathological processes. In this review, we summarize current knowledge about classifications, functions, and interactions of TRP channels and PRRs, which may provide new insights into their roles in the pathogenesis of inflammatory diseases.
Collapse
Affiliation(s)
- Huirong Han
- Department of Pharmacology; Shandong University School of Medicine; Jinan, PR China; Department of Pharmacology; Weifang Medical University; Weifang, PR China
| | - Fan Yi
- Department of Pharmacology; Shandong University School of Medicine; Jinan, PR China
| |
Collapse
|
15
|
Liu HQ, Zhang XY, Edfeldt K, Nijhuis MO, Idborg H, Bäck M, Roy J, Hedin U, Jakobsson PJ, Laman JD, de Kleijn DP, Pasterkamp G, Hansson GK, Yan ZQ. NOD2-Mediated Innate Immune Signaling Regulates the Eicosanoids in Atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 33:2193-201. [DOI: 10.1161/atvbaha.113.301715] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Hui-Qing Liu
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Xiao-Ying Zhang
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Kristina Edfeldt
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Manon Oude Nijhuis
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Helena Idborg
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Magnus Bäck
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Joy Roy
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Ulf Hedin
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Per-Johan Jakobsson
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Jon D. Laman
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Dominique P. de Kleijn
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Gerard Pasterkamp
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Göran K. Hansson
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| | - Zhong-Qun Yan
- From the Center for Molecular Medicine, Department of Medicine (H.-Q.L., X.-Y.Z., K.E., M.B., G.K.H., Z.-Q.Y.), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Division of Translational Medicine and Chemical Biology (K.E.), and Rheumatology Unit, Department of Medicine (H.I., P.-J.J.), Karolinska Institutet, Stockholm, Sweden; Department of Pharmacology, School of Medicine, Shandong University, Jinan, China (H.-Q.L.); Health Science Center, Peking University, Beijing,
| |
Collapse
|
16
|
Paparizos SC, Goldstein DA, Bouhenni RA, Steiner S, Dunmire JJ, Edward DP. Immunohistochemical Evidence of Specific Iris Involvement in Blau Syndrome. Ocul Immunol Inflamm 2012; 20:471-4. [DOI: 10.3109/09273948.2012.726391] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|